As illustrated in Figure 6B and Table 2, all vaccinated groups exhibited significantly cyst reduction compared to controls, with the bivalent formulation (pVAX-ROP6 + pVAX-MIC12) demonstrating superior protection (56.6% cyst reduction vs. controls, p < 0.01). Here, MICOS13 is linked to cyst.